jk,
no, I've been done with options for a long time--those in IDCC were too traumatic. Did watch a friend crash and burn at the top of the Nasdaq with many, many out of the money call options on Gateway (computers).
Wife and I retired in summer '06 and sold all rental houses except a personal house and two on Contract for Deeds. Spent two years traveling and fortunately for the most part was out of the market for those 24-30 months until making a big bet on Flextronics at $2.07 and averaging in more at $1.35. Got a pretty fast triple+ and have been mostly protecting those gains while continuing to travel.
I have two biotech plays in Roth/Regular IRAs I'll share-- I had three, but sold out of CYCC and it's way too over-cooked for me now.
1. BNVI now at $.60 and I think its Menerba drug so far unpartnered and scheduled to start PIII for hot flash treatments in 1 or 2Q 2010. I don't want to go all Mickey on you, but i think Menerba has a chance to be the biggest selling drug of all-time by the time Obama finishes his second term. I've been in since $.36-$.38.
2. GNVC has moved significantly since I bought at $.795 and it's $2.20 now. They just partnered yesterday with Novartis for a hearing loss drug that's in pre-clinical. Upfront payment was $5M and milestone payments could equal $213M. Royalties on top of that. It's for a pre-clinical concept not even in GNVCs main wheelhouse but probably a big pharma validation of their drug delivery platform. Their big one is called TNFerade in PIII testing. Company announced a few days ago that the topline results would be announced in 10-12 weeks--TNFerade is a gene-based treatment for Pancreatic cancer and hopefully other solid tumor apps. to come.
BNVI and GNVC are remarkably similar to me in their possibilities and I think TNFerade could be the best selling cancer treatment--again by Obamas second term end.
You asked.
I have no motives except to respond to a question.
My position is not dependent on retail investors believing in these two companies.
robj
